Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.44 USD | -1.88% | -0.10% | +25.63% |
Mar. 12 | HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating | MT |
Mar. 07 | Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.63% | 614M | C- | ||
+1.10% | 106B | B+ | ||
+9.29% | 103B | B+ | ||
-3.00% | 21.44B | B | ||
-11.89% | 22.11B | B+ | ||
-26.59% | 20.99B | A- | ||
-5.20% | 19.44B | A- | ||
-6.58% | 17.6B | B | ||
+5.83% | 13.88B | C+ | ||
+7.46% | 11.75B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock IGM Biosciences, Inc. - Nasdaq
- Ratings IGM Biosciences, Inc.